Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-01-16Clinical Trial Update: A Trial of Selinexor, Ruxolitinib and Methylprednisolone [Phase 1]
A Phase 1 clinical trial investigates a combination of selinexor, ruxolitinib, and methylprednisolone in adults with relapsed or refractory …
-
CLINICAL_TRIALS research · 2025-01-15Clinical Trial Update: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant [Phase 3]
A Phase 3 trial comparing two treatments in newly diagnosed multiple myeloma patients ineligible for transplant is currently ACTIVE_NOT_RECR…
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma [Phase 2]
A Phase 2 trial is evaluating Iberdomide in combination with Daratumumab as maintenance therapy after autologous stem cell transplant for mu…
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
This clinical trial investigates a machine learning approach to link multiple myeloma complexity with early disease recurrence. It is curren…
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex [Phase 1, Phase 2]
This clinical trial update describes a multi-center Phase 1/2 study of belantamab mafodotin in combination with pomalidomide and dexamethaso…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Study of CT071 Injection in RRMM or PPCL [EARLY_Phase 1]
Clinical trial update for CT071 injection in relapsed/refractory multiple myeloma and primary plasma cell leukemia; early-phase 1 study curr…
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) [Phase 1, Phase 2]
A Phase 1/2 clinical trial assessing safety and efficacy of an anti-BCMA/FcRL5 CAR-T cell therapy for relapsed/refractory multiple myeloma. …
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluating safety and efficacy of a fourth-generation CAR-T therapy for hematologic malignancies, including multipl…
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Longitudinal Data Registry of Plasma Cell Dyscrasia
This entry describes a longitudinal data registry study of plasma cell dyscrasias, including multiple myeloma, sponsored by Shanghai Zhongsh…
-
CLINICAL_TRIALS research · 2025-01-03Clinical Trial Update: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM [EARLY_Phase 1]
Early-phase clinical trial evaluating the safety and efficacy of a human-derived anti-BCMA CAR-T cell therapy for relapsed/refractory multip…
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: SIL as Maintenance Therapy in Multiple Myeloma [Phase 2]
Phase 2 clinical trial studying SIL as maintenance therapy for multiple myeloma; the study is currently not yet recruiting. Sponsor: Navy Ge…
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma [NA]
A clinical trial update indicates a BCMA/CD3 bispecific antibody is being studied for high-risk smoldering multiple myeloma, with the trial …
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.
This clinical trial update reports a cross-sectional study assessing the positive rate of serum M protein using a highly sensitive detection…
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma [Phase 3]
Phase 3 trial evaluating QL2109 in combination with DARZALEX FASPRO for multiple myeloma is listed as not yet recruiting.
-
CLINICAL_TRIALS research · 2024-12-18Clinical Trial Update: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone [Phase 3]
A Phase 3 clinical trial evaluating a therapy for advanced relapsed/refractory multiple myeloma with vs without dexamethasone is currently r…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma [EARLY_Phase 1]
A pilot early-phase 1 trial is investigating whether changes in serum BCMA can indicate disease progression in multiple myeloma and the stud…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS [Phase 1]
A Phase 1 study of FD-001 in recurrent/refractory acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndro…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma [EARLY_Phase 1]
This is an early-phase dose-escalation trial evaluating a CD19/CD22/BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma; rec…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
This ClinicalTrials.gov update describes a long-term safety study of Abecma (idecabtagene vicleucel) in adults with newly diagnosed multiple…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 study of IBI3003 for relapsed or refractory multiple myeloma is currently recruiting, sponsored by Innovent Biologics (Suzhou) C…
-
CLINICAL_TRIALS research · 2024-12-12Clinical Trial Update: Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
This update notes that the PaCE-MM study on patient and care partner experiences living with multiple myeloma has been terminated.
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
A completed clinical trial (NCT03848676) investigates the genomic and phenotypic determinants of resistance to immunotherapies in patients w…
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab [NA]
A real-world study of relapsed/refractory multiple myeloma patients treated with isatuximab is currently recruiting, sponsored by Pack Healt…
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients [Phase 2, Phase 3]
An ongoing Phase 2/Phase 3 trial is evaluating expression-linked and R-ISS–adapted stratification to guide first-line therapy in newly diagn…
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia
A clinical trial update from the University of Modena and Reggio Emilia shows a recruiting study at Ausl IRCCS Reggio Emilia focused on unme…